Reporting from: – San Antonio Breast Cancer Symposium, December 8-11, 2004 – European Society for Medical Oncology Congress, October 29-November 10, 2004, Vienna In this edition: Raimund J
Reporting from:
– San Antonio Breast Cancer Symposium, December 8-11, 2004
– European Society for Medical Oncology Congress, October 29-November 10, 2004, Vienna
In this edition:
Raimund Jakesz discusses the results from a combined Austrian and German study, examining the effects of switching from tamoxifen to an aromatase inhibitor in approximately 3,000 women with breast cancer.
Tony Howell talks about latest results from the ATAC trial, designed to find out whether single-agent tamoxifen or single-agent anastrazole is better at five years. Dr. Howell reports on study results at 68 months of follow-up for more than 9,000 postmenopausal women.
Thomas B. Julian gives the latest findings from the large American NSABP B-32 trial, which compared sentinel node biopsy with conventional axillary dissection.
Robert Mansel reports results from the British ALMANAC study involving 1,031 patients. This longest-running study of sentinel node biopsy comparing the method with standard axillary treatment closed in 2003.
Ivo Olivotto addresses the question of which patients having mastectomy should receive radiation, particularly if a woman has one to three positive nodes. His group analyzed data on approximately 820 women referred between 1989 and 1997, treated with mastectomy.
…